Endo announces BEMA Buprenorphine trial success; Bind stock slides after Amgen ends $180M partnership;

> A redesigned version of Covidien's ($COV) Trellis peripheral infusion system was launched commmercially, the company announced. The system is the only one of its kind that focuses on the treatment of blood clots that can lead to postthrombotic syndrome. Release

> Bind Therapeutics' ($BIND) stock fell over 10% after Amgen ($AMGN) ended a $180M collaboration. Story

> Endo Pharmaceuticals ($EDNP) announced the success of a Phase III trial of BEMA Buprenorphine, making the pain reliever ready for an FDA decision. The treatment uses delivery technology from BioDelivery Sciences International ($BDSI) and had previously failed a Phase III trial before Endo purchased rights to the drug for $180M. More

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.